Standout Papers

Phase I Study of Single-Agent Anti–Programmed Death-1 (M... 1999 2026 2008 2017 2.3k
  1. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2010)
    Julie R. Brahmer, Charles G. Drake et al. Journal of Clinical Oncology
  2. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer (2015)
    Christopher J. Sweeney, Yu‐Hui Chen et al. New England Journal of Medicine
  3. Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer (2008)
    Steven J. Cohen, Cornelis J.A. Punt et al. Journal of Clinical Oncology
  4. Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 (2008)
    Brian I. Rini, Susan Halabi et al. Journal of Clinical Oncology
  5. Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study (1999)
    Philip W. Kantoff, Susan Halabi et al. Journal of Clinical Oncology
  6. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial (2018)
    Christos E. Kyriakopoulos, Yu‐Hui Chen et al. Journal of Clinical Oncology
  7. Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303) (2010)
    Hedy L. Kindler, Donna Niedzwiecki et al. Journal of Clinical Oncology
  8. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial (2017)
    Toni K. Choueiri, Susan Halabi et al. Journal of Clinical Oncology

Immediate Impact

10 by Nobel laureates 22 from Science/Nature 105 standout
Sub-graph 1 of 17

Citing Papers

Renal cell carcinoma
2024 Standout
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
2023 Standout

Works of Joel Picus being referenced

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
2017 Standout
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
2016
and 1 more

Author Peers

Author Last Decade Papers Cites
Joel Picus 9106 8932 2465 4488 223 17.7k
Julian R. Molina 10277 7942 1388 3191 211 17.8k
Yoshitaka Fujii 8242 8943 1988 3917 436 19.6k
J. Wanders 10960 7888 2992 2723 132 19.3k
Roger B. Cohen 9018 5780 3309 1845 320 17.1k
Jennifer J. Knox 7467 8114 4255 3866 374 17.0k
David M. Nanus 4890 8050 1750 3488 326 14.4k
Patricia Troncoso 4342 7842 1670 2431 250 13.5k
Allan T. van Oosterom 9266 10029 4253 2777 88 21.6k
Daniel P. Petrylak 10847 10428 7214 3272 521 22.4k
Ezra E.W. Cohen 8308 5492 3157 1956 416 16.4k

All Works

Loading papers...

Rankless by CCL
2026